Clinical trials of lipid-lowering medication in diabetes
- 1 May 2003
- journal article
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 3 (3) , 217-220
- https://doi.org/10.1177/14746514030030031101
Abstract
Evidence that patients with type 2 diabetes can benefit from statin therapy is strong. Issues remain to be resolved about whether all patients with type 2 diabetes should receive statin treatment. For the present the National Institute for Clinical Excellence has recommended statin treatment in secondary prevention and in primary prevention when coronary heart disease (CHD) risk exceeds 15% over the next 10 years or lipid levels are high. Fibrates are a better first-line drug therapy when triglycerides exceed 10 mmol/L. Consideration should also be given to combining a fibrate with a statin in patients with CHD whose triglycerides exceed 2.3 mmol/L despite statin treatment, but this requires careful monitoring for myositis. Clinical guidelines are needed for the use of lipid-lowering medication in type 1 diabetes.This publication has 25 references indexed in Scilit:
- Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)JAMA, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial InfarctionCirculation, 2002
- Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetesDiabetic Medicine, 2002
- Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease PreventionCurrent Medical Research and Opinion, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemiaHeart, 2001
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994
- WHO clofibrate/cholesterol trial: clarificationsThe Lancet, 1992